Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Mar 11.
doi: 10.1097/PCC.0000000000003926. Online ahead of print.

Sweep Gas Nitric Oxide During Extracorporeal Membrane Oxygenation in Neonates and Children (NECTAR Trial): A Single-Center, Pilot Randomized Controlled Trial

Adrian C Mattke  1   2 , Kerry Johnson  1   2 , Kristen Gibbons  3 , Renate Le Marsney  3 , Debbie A Long  4 , Christopher O'Brien  5 , Antje Blumenthal  6 , Prem S Venugopal  7 , Nelson Alphonso  7 , Luregn J Schlapbach  3   8
Affiliations

Sweep Gas Nitric Oxide During Extracorporeal Membrane Oxygenation in Neonates and Children (NECTAR Trial): A Single-Center, Pilot Randomized Controlled Trial

Adrian C Mattke et al. Pediatr Crit Care Med. .

Abstract

Objectives: To test the feasibility and safety of a randomized controlled trial (RCT) delivering nitric oxide into the sweep gas of extracorporeal membrane oxygenation (ECMO) circuits (sNO) in critically ill children. Second, we explored whether use of sNO may influence clinical outcomes.

Design: Prospective pilot single-center open-label RCT (trial registration number ACTRN12619001518156).

Setting: Single-center, tertiary PICU with enrollment between July 2020 and July 2023.

Patients: Patients from birth to 16 years requiring venoarterial or venovenous ECMO support were enrolled.

Interventions: Randomization to sweep flow with an oxygen/nitrogen mix vs. a mix of oxygen, nitrogen and sNO (20 parts per milliion). Randomization was stratified by type of ECMO support (venoarterial vs. venovenous).

Measurements and main results: Of 60 eligible patients 53 underwent randomization. The median (interquartile range [IQR]) was 1 month (0.1-33.5 mo) and 6.2 months (0.5-120.2 mo) for the intervention and control arms, respectively. Venoarterial and venovenous support were used in 35 of 53 (65%) and 18 of 53 (35%) patients, respectively. In all, 17 of 53 (32%) received pulmonary, 23 of 53 (43%) cardiac and 13 of 53 (25%) extracorporeal cardiopulmonary resuscitation support. Median (IQR) survival free of ECMO and survival free of PICU censored at 30 and 90 days were similar: 18.2 days (0-25.2 d) and 69.1 days (0-85.2 d) vs. 20.8 days (0-26.3 d) and 77.7 days (0-85.9 d) with an effect estimate of -3.2 days (-16.6 to 10.1 d) and -8.8 days (-54.2 to 36.6 d) between the intervention and standard care arm. Blood product use, circuit duration to replacement, free plasma hemoglobin, degree of oxygenator thrombus, and incidence of methemoglobinemia were similar between the two groups. No major adverse events occurred related to the treatment allocation or intervention.

Conclusions: This single-center pilot RCT of sNO vs. standard sweep flow in the ECMO circuit demonstrated that such a trial is safe and feasible. However, given no effect of sNO on clinical outcomes was detected further exploration of dose and route of administration of NO should be undertaken before larger, definitive trials are conducted.

Keywords: anticoagulation; child; extracorporeal life support; infant; inflammation; nitric oxide.

PubMed Disclaimer

Conflict of interest statement

Drs. Mattke, Gibbons, and Le Marsney received support for this article’s research from the Children’s Hospital Foundation. Drs. Mattke and Le Marsney received support for article research from the Thrombosis and Haemostasis Society of Australia and New Zealand for the conduct of the Nitric Oxide on Extracorporeal Membrane Oxygenation in Neonates and Children (NECTAR) trial. Dr. Gibbons’ institution received funding from the Children’s Hospital Foundation; she is supported by a National Health and Medical Research Council (NHMRC) Emerging Leader Fellowship. Dr. Blumenthal acknowledges support through an Australian Research Council Future Fellowship (FT220100487) and by the Frazer Institute, The University of Queensland. Dr. Schlapbach received support from an NHMRC Practitioner Fellowship by the Children`s Hospital Foundation, Brisbane, QLD, Australia, the NOMIS Foundation, and the Thomas and Doris Ammann Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Chatauret N, Badet L, Barrou B, et al.: Ischemia-reperfusion: From cell biology to acute kidney injury. Prog Urol 2014; 24(Suppl 1):S4–S12
    1. Kalogeris T, Baines CP, Krenz M, et al.: Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298:229–317
    1. Millar JE, Fanning JP, McDonald CI, et al.: The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology. Crit Care 2016; 20:387
    1. Schlapbach LJ, Gibbons KS, Horton SB, et al.; NITRIC Study Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), and the ANZICS Paediatric Study Group (PSG): Effect of nitric oxide via cardiopulmonary bypass on ventilator-free days in young children undergoing congenital heart disease surgery: The NITRIC randomized clinical trial. JAMA 2022; 328:38–47
    1. Lei C, Berra L, Rezoagli E, et al.: Nitric oxide decreases acute kidney injury and stage 3 chronic kidney disease after cardiac surgery. Am J Respir Crit Care Med 2018; 198:1279–1287

LinkOut - more resources